Cytosorbents Co. (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 11,176 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $8.25, for a total value of $92,202.00. Following the completion of the sale, the chief financial officer now directly owns 261,246 shares of the company’s stock, valued at approximately $2,155,279.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Cytosorbents stock traded up $0.15 during midday trading on Thursday, hitting $7.70. 114,023 shares of the company were exchanged, compared to its average volume of 181,172. Cytosorbents Co. has a fifty-two week low of $3.30 and a fifty-two week high of $8.25. The firm has a market capitalization of $223.98, a PE ratio of -24.06 and a beta of -0.09. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.54 and a current ratio of 2.64.
Cytosorbents (NASDAQ:CTSO) last announced its earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. The business had revenue of $4.65 million during the quarter, compared to analyst estimates of $4.56 million. analysts forecast that Cytosorbents Co. will post -0.47 earnings per share for the current fiscal year.
CTSO has been the subject of several research reports. B. Riley set a $11.00 price target on Cytosorbents and gave the stock a “buy” rating in a research note on Friday, December 22nd. Maxim Group set a $12.00 target price on shares of Cytosorbents and gave the company a “buy” rating in a research note on Friday, March 9th. ValuEngine upgraded Cytosorbents from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Cowen set a $9.00 price target on Cytosorbents and gave the company a “buy” rating in a report on Thursday, March 8th. Finally, HC Wainwright set a $14.00 price target on Cytosorbents and gave the company a “buy” rating in a report on Friday, March 9th. Six research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $11.05.
Several hedge funds have recently bought and sold shares of CTSO. Wealthcare Advisory Partners LLC acquired a new stake in shares of Cytosorbents during the 3rd quarter valued at approximately $365,000. Skylands Capital LLC raised its position in shares of Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock valued at $4,716,000 after acquiring an additional 225,558 shares in the last quarter. Fortaleza Asset Management Inc. raised its position in shares of Cytosorbents by 60.9% during the 4th quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 14,240 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Cytosorbents by 182.3% during the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 13,515 shares in the last quarter. Finally, B. Riley Financial Inc. acquired a new stake in shares of Cytosorbents during the 4th quarter valued at approximately $992,000. 10.84% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Cytosorbents Co. (NASDAQ:CTSO) CFO Sells 11,176 Shares of Stock” was first posted by Macon Daily and is owned by of Macon Daily. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://macondaily.com/2018/04/12/kathleen-p-bloch-sells-11176-shares-of-cytosorbents-corp-ctso-stock-updated-updated-updated.html.
Cytosorbents Company Profile
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.